Uncategorized

DiNAQOR has acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company.

DiNAQOR announced that it will establish its own GMP manufacturing capabilities with a new 1200 sqm (13,000 sq. ft) GMP facility in the Bio-Technopark Schlieren-Zürich

DiNAQOR CEO Johannes Holzmeister discusses the company’s innovative gene therapy platform, recent partnerships and how DiNAQOR is uniquely positioned to deliver successful treatments for patient’s suffering from heart failure with Nature Research.

DiNAQOR CSO Thomas Voit discusses trends in cardiovascular gene therapy and the company’s partnership with BioMarin with Nature Research.

DiNAQOR announced that Eduard Ayuso, D.V.M., Ph.D. has been appointed as Chief Technology Officer.

DiNAQOR announced the expansion of its global research and development operations with a new facility in the Bio-Technopark Schlieren-Zürich.

BioMarin Pharmaceutical has entered into a preclinical collaboration and license agreement with DiNAQOR to develop novel gene therapies to treat rare genetic cardiomyopathies.

DiNAQOR today announced a research collaboration and exclusive license agreement with UCL to develop novel gene therapies for the treatment of monogenic cardiomyopathies

Strategic collaboration to focus on DiNAQOR’s adeno-associated virus gene therapy production system Companies to partner on gene therapy process and analytical development for preclinical, clinical and commercial production of DiNA-001, DiNAQOR’s lead preclinical program Process development and manufacturing to be located at Lonza, Houston (US), Center of Excellence for cell-and-gene-therapy manufacturing Quote from Alberto Santagostino, … Read more